和邦生物：股价异常波动，预亏且有减持计划未完成

Core Viewpoint - The company announced significant stock price fluctuations and projected substantial losses for the fiscal year 2025, while also planning to reduce its repurchased shares in the near future [1] Group 1: Stock Price Fluctuation - The company's stock price experienced a cumulative deviation of over 20% across three consecutive trading days from February 24 to 26, 2026, indicating unusual volatility [1] Group 2: Financial Performance - The preliminary estimate for the company's net profit attributable to shareholders for the fiscal year 2025 is expected to be a loss between 470 million to 570 million yuan, with the non-recurring net profit loss projected to be between 460 million to 560 million yuan [1] Group 3: Share Reduction Plan - The company plans to reduce its previously repurchased shares by up to 177 million shares, which does not exceed 2% of the total share capital, with the reduction scheduled between March 2 and September 1, 2026; this plan has not yet been fully implemented [1]